Trial record 1 of 1 for:    NCT01683188
Previous Study | Return to List | Next Study

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY 01)

This study has been terminated.
(A shift in the melanoma treatment landscape adversely affected accrual & to early closure.)
Information provided by (Responsible Party):
Prometheus Laboratories Identifier:
First received: September 7, 2012
Last updated: February 3, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)